arbeiten mit Gentechnik im Agrarbereich,also sehr heiss und nur ne kleine Firma mit wenig Geld und einer einzigen Technik bisher
Laws or public sentiment may limit our production of genetically engineered agricultural products in the future, and these laws could reduce our ability to sell these products.
Cash and cash equivalents 2002
15,348 $
Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors.
We began operations in 1995 and are at an early stage of development. We have incurred significant losses to date, and our revenues have been generated from Universal GeneTools™ collaborators, strategic partners and government research grants.
Total revenues decreased to $1.9 million in the nine months ended September 30, 2002 from $2.7 million in the corresponding period in 2001. The decrease in revenues in the nine months ended September 30, 2002 was principally due to reduced revenues recognized from collaborative agreements. We anticipate continued revenues from existing and new collaboration agreements, and we have applied for and plan to continue to apply for government
Our Universal GeneTools™ collaborations permit us to introduce our technology to many companies by supplying them with a specified ZFP TF for a payment without licensing our technology. The collaboration agreements, however, are of limited scope. Under most of our current Universal GeneTools™ collaborations we receive a payment for supplying ZFP TFs for gene targets specified by the companies.
We intend to conduct proprietary research programs to discover therapeutic product candidates.
old.edgarpro.com/edgar_conv_html/2002/11/...IS_TOP_OF_DOCUMENT